Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically confirmed prostate cancer

- At least 4 metastatic lesions identified by conventional imaging with bone
scintigraphy

- Treatment-naive disease

PATIENT CHARACTERISTICS:

- WHO performance status 0-2

- Life expectancy ≥ 12 weeks

- Hemoglobin ≥ 9.0 g/dL

- Platelet count ≥ 100 x 10^9/L

- Serum bilirubin ≤ 1.5 times upper limit of normal (ULN)

- ALT and AST ≤ 2.5 times ULN (≤ 5 times ULN if due to tumor)

- Fertile patients must use two forms of effective contraception 2 weeks prior to,
during, and for 6 months after completion of study therapy

- None of the following conditions that would prevent compliance with the study
protocol:

- Diabetes

- High levels of pain/discomfort

- Urinary incontinence

- No history of recent significant cardiac arrhythmia

- No concurrent congestive heart failure or prior history of NYHA class III-IV cardiac
disease

- No other condition that, in the investigator's opinion, would not make the patient a
good candidate for the clinical trial

PRIOR CONCURRENT THERAPY:

- No prior radiotherapy, hormone therapy, chemotherapy, endocrine therapy, or
immunotherapy for the treatment of prostate cancer

- No major thoracic and/or abdominal surgery from which the patient has not yet
recovered

- No concurrent anticancer therapy

- No concurrent hormone therapy

- No concurrent participation or planning to participate in another interventional
clinical trial

- Concurrent participation in an observational trial allowed

- No other concurrent investigational drugs